Drug firm Lupin today said it has received final approval from US health regulator to market Nabumetone tablets, used in treating arthritis, in the American market.
The company's unit, Lupin Pharmaceuticals Inc has been granted final approval by US Food and Drug Administration for Nabumetone tablets in strengths of 500mg and 750mg, Lupin said in a statement.
The Mumbai-headquartered firm Nabumetone is the generic equivalent of GlaxoSmithKline's Relafen tablets, indicated for acute and chronic treatment of osteoarthritis and rheumatoid arthritis.
According to IMS Health sales data, the annual sales for Nabumetone in the US was $66.8 million for the 12-month period ended September 2010.
Shares of Lupin were today trading at Rs 468.40 on Bombay Stock Exchange in the late afternoon trade, up 0.36 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app